New hope for breast cancer patients with brain tumors
NCT ID NCT05866432
Summary
This study is testing whether a drug called datopotamab-deruxtecan can shrink breast cancer tumors that have spread to the brain. It's for people with a hard-to-treat type called triple-negative breast cancer who have new or growing brain metastases. The main goal is to see how well the drug works inside the brain, and researchers will also track side effects and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology
RECRUITINGVienna, Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.